Novo nordisk (nvo) faces securities class action after weight loss therapy trial data disappoints, analyst questions trial's design – hagens berman

San francisco, jan. 28, 2025 (globe newswire) -- novo nordisk a/s (nyse: nvo) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, cagrisema.

NVO Ratings Summary

NVO Quant Ranking